The diagnosis of viral pathogens is a crucial component of plant biosecurity surveillance and preventing the introduction of exotic plant viruses and viroids at the border. Existing quarantine procedures can be time-consuming and require detailed knowledge of potential infecting viral pathogens. Currently, imported plants can spend as long as two years in quarantine, with associated costs.
To simplify the post-entry quarantine process researchers have developed a plant diagnostic toolkit for plant viruses and viroids. The toolkit takes advantage of the natural antiviral system of plants, using small RNA next generation sequencing (sRNA-seq) technology to detect nearly all known viruses and viroids in a single test. The new test, and associated toolkit, will reduce the time imported plant material spends in Australia’s quarantine system while improving accuracy of detection in a single sRNA-seq experiment.
Validating microbiome claims – including the latest DNA techniquesEagle Genomics
Abel Ureta-Vidal, Founder and CEO of Eagle Genomics, discusses how advanced DNA techniques help us to identify and characterise the microbiome, leading us to ways to prove cosmetic claims at the in-cosmetics formulation summit, 25th October 2017.
Digital transformation of translational medicineEagle Genomics
Anthony Finbow, Executive Chairman, and William Spooner, Chief Science Officer, discuss Eagle Genomics' software product, marketed at pharmaceutical and biotech companies, which enables radical improvements in the productivity of scientific research.
HiPerMAb: A statistical tool for judging the potential of short fat dataLEGATO project
Abstract: Common statistical approaches are not designed to deal with so-called “short fat data” in biomarker pilot studies, where the number of biomarker candidates exceeds the sample size by magnitudes. Because of the high cost and long time to collect and prepare the data in this type of study, researchers prefer to check the potential of the large set of biomarker candidates in a small pilot study.
The aim of the pilot study is to answer the question whether it is worthwhile to extend the study to a larger study and to obtain information about the required sample size. HiPerMAb tool is proposed as method to judge the potential in a small biomarker pilot study without the need to explicitly identifying and confirming a specific subset of biomarkers. It allows to evaluate pilot studies based on performance measures like multiclass AUC, entropy, area above the cost curve, hypervolume under manifold and misclassification rate. Entropy is a useful tool in machine learning and became one of the most exciting developments in biology today. However, it has no closed form solution like area under the ROC curve (AUC) to estimate the required p-values for HiPerMAb. The possible solution is the simulations, Monte Carlo simulations, and with such number of biomarker candidates in such studies the number of simulation become significantly large, computational cost, and energy consuming. By using Maxeller DFE on Jülich testbed, we are able to look at study with more than 50,000 biomarkers so we need to estimate a probability smaller than 1/50000, which means we need to run up to 50 million simulations. Then number of “good” biomarker candidates is compared to the expected number of “good” biomarker candidates in a dataset with no association to the considered disease states to judge if the study is worthy to be extended with appropriate sample size to find and evaluate a final combination of biomarkers with high predictive value.
Poster presented by Amani Al-Mekhlafi at the LEGaTO Final Event: 'Low-Energy Heterogeneous Computing Workshop'
Considerations and challenges in building an end to-end microbiome workflowEagle Genomics
Many of the data management and analysis challenges in microbiome research are shared with genomics and other life-science big-data disciplines. However there are aspects that are specific: some are intrinsic to microbiome data, some are related to the maturity of the field, with others related to extracting business value from the data.
Expert Panel on Data Challenges in Translational ResearchEagle Genomics
A panel of experts including Alexandre Passioukov, VP Translational Medicine at Pierre Fabre, Xose Fernandez, Chief Data Officer at Institut Curie, Abel Ureta-Vidal, CEO at Eagle Genomics share their first-hand experience of enabling translational research in pharmaceutical and biomedical organisations, and discuss the challenges around the establishment of streamlined, seamless data handling and governance to accelerate innovation.
The diagnosis of viral pathogens is a crucial component of plant biosecurity surveillance and preventing the introduction of exotic plant viruses and viroids at the border. Existing quarantine procedures can be time-consuming and require detailed knowledge of potential infecting viral pathogens. Currently, imported plants can spend as long as two years in quarantine, with associated costs.
To simplify the post-entry quarantine process researchers have developed a plant diagnostic toolkit for plant viruses and viroids. The toolkit takes advantage of the natural antiviral system of plants, using small RNA next generation sequencing (sRNA-seq) technology to detect nearly all known viruses and viroids in a single test. The new test, and associated toolkit, will reduce the time imported plant material spends in Australia’s quarantine system while improving accuracy of detection in a single sRNA-seq experiment.
Validating microbiome claims – including the latest DNA techniquesEagle Genomics
Abel Ureta-Vidal, Founder and CEO of Eagle Genomics, discusses how advanced DNA techniques help us to identify and characterise the microbiome, leading us to ways to prove cosmetic claims at the in-cosmetics formulation summit, 25th October 2017.
Digital transformation of translational medicineEagle Genomics
Anthony Finbow, Executive Chairman, and William Spooner, Chief Science Officer, discuss Eagle Genomics' software product, marketed at pharmaceutical and biotech companies, which enables radical improvements in the productivity of scientific research.
HiPerMAb: A statistical tool for judging the potential of short fat dataLEGATO project
Abstract: Common statistical approaches are not designed to deal with so-called “short fat data” in biomarker pilot studies, where the number of biomarker candidates exceeds the sample size by magnitudes. Because of the high cost and long time to collect and prepare the data in this type of study, researchers prefer to check the potential of the large set of biomarker candidates in a small pilot study.
The aim of the pilot study is to answer the question whether it is worthwhile to extend the study to a larger study and to obtain information about the required sample size. HiPerMAb tool is proposed as method to judge the potential in a small biomarker pilot study without the need to explicitly identifying and confirming a specific subset of biomarkers. It allows to evaluate pilot studies based on performance measures like multiclass AUC, entropy, area above the cost curve, hypervolume under manifold and misclassification rate. Entropy is a useful tool in machine learning and became one of the most exciting developments in biology today. However, it has no closed form solution like area under the ROC curve (AUC) to estimate the required p-values for HiPerMAb. The possible solution is the simulations, Monte Carlo simulations, and with such number of biomarker candidates in such studies the number of simulation become significantly large, computational cost, and energy consuming. By using Maxeller DFE on Jülich testbed, we are able to look at study with more than 50,000 biomarkers so we need to estimate a probability smaller than 1/50000, which means we need to run up to 50 million simulations. Then number of “good” biomarker candidates is compared to the expected number of “good” biomarker candidates in a dataset with no association to the considered disease states to judge if the study is worthy to be extended with appropriate sample size to find and evaluate a final combination of biomarkers with high predictive value.
Poster presented by Amani Al-Mekhlafi at the LEGaTO Final Event: 'Low-Energy Heterogeneous Computing Workshop'
Considerations and challenges in building an end to-end microbiome workflowEagle Genomics
Many of the data management and analysis challenges in microbiome research are shared with genomics and other life-science big-data disciplines. However there are aspects that are specific: some are intrinsic to microbiome data, some are related to the maturity of the field, with others related to extracting business value from the data.
Expert Panel on Data Challenges in Translational ResearchEagle Genomics
A panel of experts including Alexandre Passioukov, VP Translational Medicine at Pierre Fabre, Xose Fernandez, Chief Data Officer at Institut Curie, Abel Ureta-Vidal, CEO at Eagle Genomics share their first-hand experience of enabling translational research in pharmaceutical and biomedical organisations, and discuss the challenges around the establishment of streamlined, seamless data handling and governance to accelerate innovation.
This research will investigate technologies to enable the development of spore traps capable of in-field detection, and identification, of specific biosecurity threats.
OECD Webinar | From Data to Knowledge and Beyond Adverse Outcome Pathways as ...OECD Environment
On 23 and 30 November 2020, the OECD hosted a webinar on training needs, resources, and opportunities for adverse outcomes pathways (AOPs). This interactive webinar discussed opportunities for expanding the AOP community of trainers to meet current needs, considering all available resources.
The objectives of this webinar were to:
- outline past and current training activities
- receive your input on experiences in conducting and/or receiving training; and
- gather your views, needs and ideas for the provision of training in the future.
Watch the webinar video recording at: https://youtu.be/7ObxATifDds.
El 12 de mayo de 2017 celebramos en la Fundación Ramó Areces una jornada con IS Global y Unitaid sobre enfermedades transmitidas por vectores, como la malaria, entre otras.
Pine.Bio slide deck - Idea Village CAPITALx (New Orleans Entrepreneur Week 2017)Elia Brodsky
Pine.Bio is changing the clinical bioinformatics speace by applying it's unique biAssociation engine to identify meaningful links between omics and clinical data, empowering better decisions and providing more options to patients.
BUILD-AMR: Mitigating agriculture-associated antimicrobial resistance in poul...ILRI
Poster prepared by B. Wieland, A. Moodley, I. Mbatidde, D. Ndoboli, B-A Tenhagen, U.Roesler, R. Erechu, A. Litta-Mulondo, S. Kakooza, J. Waiswa and C. Kankya for the Virtual Annual Planning Meeting ILRI/BMZ Program, Boosting Uganda’s Investment for Livestock Development (BUILD), 10–12 June 2020
BioVariance - Pediatric Pharmacogenomics in Drug DiscoveryJosef Scheiber
This slideset gives an overview of pharmacogenomic and pediatric dosing knowledge and various influence factors. Finally it shows an example on how to use this kind of Data within predictive approaches.
Find out about collaboration and partnership opportunities with the Wellcome Sanger Institute that aims to create exceptional healthcare opportunities for everyone from extraordinary science.
Surveillance systems are an essential component of biosecurity. Design of biosecurity surveillance systems may include designs of grids of static traps, plans for field sampling, or deployment of potentially "game-changing" mobile trap technology. The aim of these systems is to achieve defined detection objectives, (e.g. early detection, supporting area-freedom status) at minimum cost. This project will develop and apply statistically-based surveillance systems that account for organism biology, trap behaviour and landscape characteristics.
Enhancing collaboration in informatics solutions
Now more than ever, the need for establishing connections and closer collaboration is a priority for many organisations. This webinar will highlight how Medicines Discovery Catapult is looking to approach the issue of ensuring the right problems are being tackled by the right experts.
Presented by Mark Davies on 30th April 2020
2016 Data Commons and Data Science Workshop June 7th and June 8th 2016. Genomic Data Commons, FAIR, NCI and making data more findable, publicly accessible, interoperable (machine readable), reusable and support recognition and attribution
This research will investigate technologies to enable the development of spore traps capable of in-field detection, and identification, of specific biosecurity threats.
OECD Webinar | From Data to Knowledge and Beyond Adverse Outcome Pathways as ...OECD Environment
On 23 and 30 November 2020, the OECD hosted a webinar on training needs, resources, and opportunities for adverse outcomes pathways (AOPs). This interactive webinar discussed opportunities for expanding the AOP community of trainers to meet current needs, considering all available resources.
The objectives of this webinar were to:
- outline past and current training activities
- receive your input on experiences in conducting and/or receiving training; and
- gather your views, needs and ideas for the provision of training in the future.
Watch the webinar video recording at: https://youtu.be/7ObxATifDds.
El 12 de mayo de 2017 celebramos en la Fundación Ramó Areces una jornada con IS Global y Unitaid sobre enfermedades transmitidas por vectores, como la malaria, entre otras.
Pine.Bio slide deck - Idea Village CAPITALx (New Orleans Entrepreneur Week 2017)Elia Brodsky
Pine.Bio is changing the clinical bioinformatics speace by applying it's unique biAssociation engine to identify meaningful links between omics and clinical data, empowering better decisions and providing more options to patients.
BUILD-AMR: Mitigating agriculture-associated antimicrobial resistance in poul...ILRI
Poster prepared by B. Wieland, A. Moodley, I. Mbatidde, D. Ndoboli, B-A Tenhagen, U.Roesler, R. Erechu, A. Litta-Mulondo, S. Kakooza, J. Waiswa and C. Kankya for the Virtual Annual Planning Meeting ILRI/BMZ Program, Boosting Uganda’s Investment for Livestock Development (BUILD), 10–12 June 2020
BioVariance - Pediatric Pharmacogenomics in Drug DiscoveryJosef Scheiber
This slideset gives an overview of pharmacogenomic and pediatric dosing knowledge and various influence factors. Finally it shows an example on how to use this kind of Data within predictive approaches.
Find out about collaboration and partnership opportunities with the Wellcome Sanger Institute that aims to create exceptional healthcare opportunities for everyone from extraordinary science.
Surveillance systems are an essential component of biosecurity. Design of biosecurity surveillance systems may include designs of grids of static traps, plans for field sampling, or deployment of potentially "game-changing" mobile trap technology. The aim of these systems is to achieve defined detection objectives, (e.g. early detection, supporting area-freedom status) at minimum cost. This project will develop and apply statistically-based surveillance systems that account for organism biology, trap behaviour and landscape characteristics.
Enhancing collaboration in informatics solutions
Now more than ever, the need for establishing connections and closer collaboration is a priority for many organisations. This webinar will highlight how Medicines Discovery Catapult is looking to approach the issue of ensuring the right problems are being tackled by the right experts.
Presented by Mark Davies on 30th April 2020
2016 Data Commons and Data Science Workshop June 7th and June 8th 2016. Genomic Data Commons, FAIR, NCI and making data more findable, publicly accessible, interoperable (machine readable), reusable and support recognition and attribution
NCI Cancer Genomics, Open Science and PMI: FAIR Warren Kibbe
Talk given to the NLM Fellows on July 8, 2016. Touches on Cancer Genomics, Open Science and PMI: FAIR in NCI genomics thinking and projects. Includes discussion of the Genomic Data Commons (GDC), Cancer Data Ecosystem, Data sharing, and the NCI cancer clinical trials open API.
Collaboraive sharing of molecules and data in the mobile ageSean Ekins
An overview of using collaborative software in small and large scale collaborations in drug discovery. A focus on Tuberculosis. Also analysis of collaboration and mobile apps for science
Lessons from the UK: Data access, patient trust & real-world impact with heal...Varsha Khodiyar
Slides supporting presentation given at the virtual Beilstein Open Science Symposium in October 2021.
Abstract:
Health Data Research UK’s mission is to unite the UK’s health data to enable discoveries that improve people’s lives. Our 20-year vision is for large scale data and advanced analytics to benefit every patient interaction, clinical trial, biomedical discovery and enhance public health. A key part of HDR UK’s vision is our data portal, the Innovation Gateway. The Gateway facilitates discovery of healthcare data and simplifies data request procedures across multiple data custodians. The Gateway contains metadata on a variety of datasets, including those related to COVID-19, cardiovascular, maternal health, emergency care, primary care, secondary care, acute care, palliative care, biobanks, research cohorts and deeply phenotyped patient cohorts.
From the outset HDR UK has sought the voices, views and experiences of patient and lay-public groups to ensure there is transparency and clear public benefit in the use of the UK’s health data. Patient and public involvement is key to making the Gateway accessible, transparent and to ensure public confidence in research access to health data. The importance of public outreach combined with providing research access to data is illustrated with HDR UK’s contribution to the UK’s coronavirus pandemic response. HDR UK was tasked by the UK’s Chief Scientific Office to build and facilitate the infrastructure to support the National Core Studies, providing key insights on the evolving situation to UK policy makers during the course of the pandemic.
In this talk, I will show how HDR UK is enabling open science by facilitating the discovery of health data, and simplifying the process of requesting access to multiple datasets. I’ll discuss HDR UK’s approach to embedding transparency on research data usage for patients and public, and summarise some of the key ways in which HDR UK has contributed to the coronavirus pandemic.
A detailed summary of Data-driven systems medicine workshop which took place on June 11-12th at the Cardiff University Brain Research Imaging Centre. The event brought together experts from Academia and Industry who all recognised the potential that AI, ML and systems modelling can unlock for personalised medicine. The event was sponsored by DELL EMC and Partners. Partners included Supercomputing Wales, Advanced Research Computing @ Cardiff, Systems Immunity Research Institute, Cardiff Institute of Tissue Engineering and Research and British Society of Immunology South Wales Group.
Data-integration platform for cancer research:cBioPortal demoCORBEL
Participants will be introduced to the data-integration platform cBioPortal. Here, different sources of research data (clinical, imaging, biosample and experimental) of a study are integrated, enabling viewing, querying and analysis.
This webinar is aimed at data managers, researchers, PhD students and postdocs involved in clinical, translational and biomedical research.
Improvements in sequencing technologies have led to a deluge of genomics data in many fields of research. Specifically, the increasing size of cancer-related genomics datasets require comprehensive software solutions that remain accessible to clinical researchers. Clearly, there is an obvious need for tools that integrate genomics and other molecular biology results with the phenotypic and clinical outcome data. During this webinar, the cBio Cancer Genomics Portal (cBioPortal) will be introduced through a practical use case.
The cBioPortal is an open source data integration platform that enables researchers to view, query, analyse and share complex genomic cancer datasets in a user-friendly manner. The platform was originally developed by Memorial Sloan Kettering Cancer Center (New York, USA)1 and is actively maintained and further developed by an international community. The original instance of cBioPortal (http://cbioportal.org) currently provides access to data from almost 83000 tumor samples from 273 public studies.
The demo will include:
· short introduction on the FAIR principles (Findable, Accessible, Interoperable, Reusable)
· navigation through a public study on the data-integration platform cBioPortal
· recreation of select plots from publications of interest using cBioPortal functionalities
The CORBEL webinar series aims to address challenges and share best practice between biological and medical research infrastructures. The series is aimed at technical operators of RIs and is aligned with the CORBEL competency framework.
Clinical trial data wants to be free: Lessons from the ImmPort Immunology Dat...Barry Smith
Presentation to the Clinical and Research Ethics Seminar, Clinical and Translational Science Center, Buffalo, January 21, 2014
https://immport.niaid.nih.gov/
http://youtu.be/booqxkpvJMg
GenomeTrakr: Perspectives on linking internationally - Canada and IRIDA.cafionabrinkman
Talk at GenomeTrakr network meeting Sept 23 2015 in Washington DC. On Canada's open source Integrated Rapid Infectious Disease Analysis (IRIDA) bioinformatics platform - aiding genomic epidemiology analysis for public health agencies with planned open data release and linkage to GenomeTrakr. Discussed perspectives, challenges, solutions for getting more GenomeTrakr participation internationally.
Presentation from AAPS PharmSci360 (October 23, 2023) in which I describe highlights of my Springer/AAPS book Winning Grants (https://link.springer.com/book/10.1007/978-3-031-27516-6) - presenting a 'how to' guide on writing small business grants - e.g. NIH STTR and SBIR grants. Written by someone experienced in winning such grants.
Evaluating Multiple Machine Learning Models for Biodegradation and Aquatic To...Sean Ekins
The presentation was given at SETAC 2022 Nov 16 and describes our work on Evaluating Multiple Machine Learning Models for Biodegradation and Aquatic Toxicity.
We generated many models that are available to license in our MegaTox software. We found that the support vector machines performed the best after assessing many algorithms for both classification and regression models.
The authors of this work are Thomas R Lane, Fabio Urbina and Sean Ekins.
The contact is sean@collaborationspharma.com
A presentation at the Global Genes rare drug development symposium on governm...Sean Ekins
This presentation from June 12 2020 gives a brief overview of my experience of 15 years of applying for government grants to fund small companies. Prior to this I had no experience of applying for such grants. The bottom line for rare disease groups / families is find a scientist that can do this or assist you. please also see www.collaborationspharma.com
Leveraging Science Communication and Social Media to Build Your Brand and Ele...Sean Ekins
Slides from AAPS Careers session by Maren Katherina Preis, Kyle Bagin, Sean Ekins
Provides some clear steps on how you could use social media to help your career.
Oral presentation given in MEDI session at 2017 ACS in DC.
co-authors Kimberley M. Zorn, Mary A. Lingerfelt, Jair L. de Siqueira-Neto, Alex M. Clark, Sean Ekins
describes drug repurposing and machine learning - for more details see www.collaborationspharma.com
Assay Central: A New Approach to Compiling Big Data and Preparing Machine Lea...Sean Ekins
Oral presentation at 2017 ACS in DC - given by Kimberley Zorn
co-authors include Mary A. Lingerfelt, Alex M. Clark, Sean Ekins
for more details see www.collaborationspharma.com
Five Ways to Use Social Media to Raise Awareness for Your Paper or ResearchSean Ekins
Presentation given at the AAPS 2016 conference in Denver. Some of the slides are from AAPS, Some from Kudos and some from Figshare. One slide is from Tony Williams. All slides used with permission.
CDD: Vault, CDD: Vision and CDD: Models software for biologists and chemists ...Sean Ekins
A perspective on 12 yrs of CDD and developing products and collaborations.
A presentation given at the ACS meeting in San Diego - small business section
This presentation summarizes some early efforts on an open drug discovery collaboration between scientists in Brazil and the US. The amazing virus images were created by John Liebler and can be licensed from him http://www.artofthecell.com/animation/will-the-real-zika-virus-please-stand-up
The homology models were created with Swiss Model by Sean Ekins:
Marco Biasini, Stefan Bienert, Andrew Waterhouse, Konstantin Arnold, Gabriel Studer, Tobias Schmidt, Florian Kiefer, Tiziano Gallo Cassarino, Martino Bertoni, Lorenza Bordoli, Torsten Schwede. (2014). SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Research; (1 July 2014) 42 (W1): W252-W258; doi: 10.1093/nar/gku340.
Arnold K., Bordoli L., Kopp J., and Schwede T. (2006). The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling. Bioinformatics, 22,195-201.
Kiefer F, Arnold K, Künzli M, Bordoli L, Schwede T (2009). The SWISS-MODEL Repository and associated resources. Nucleic Acids Research. 37, D387-D392.
Guex, N., Peitsch, M.C., Schwede, T. (2009). Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: A historical perspective. Electrophoresis, 30(S1), S162-S173.
Ensuring Chemical Structure, Biological Data and Computational Model Quality
A talk given at SLAS 2016 mon Jan 25th in San Diego
covers published work and recent forays with BIA 10-2474
Pros and cons of social networking for scientistsSean Ekins
Over the past 4 years I have been using social networking tools for scientists more inspired by Antony Williams. I realized I am using many tools and there are pros and cons of them. Here is my brief summary.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
1. Using the CDD Vault for MM4TB
Sean Ekins PhD, DSc.
CSO, Collaborative Drug Discovery, Inc
Burlingame, CA
2. The Exploitation pathway…
Torbjörn Ingemansson
European Commission
Sean Ekins
Collaborative Drug Discovery, Inc.
Claire Skentelbery
European Biotechnology Network
Bonny Harbinger
National Institutes of Health
3. “by provisioning the right amount of storage and compute resources, cost can be significantly
reduced with no significant impact on application performance”
4. CDD- a decade of drug
discovery collaborations2004 - present
SaaS
Easy to use
Used by Academia
Industry, Biotech
Private
Selective
collaboration
100’s of published
datasets
5.
6. NIH funded STTR collaboration
Some
collaborations
outside also
1R41AI088893-01
2R42AI088893-02
Developing molecules for TB
Using computational data mining
New technologies for TB drug discovery
7. From Desktop to Mobile apps – making data accessible
Clark et al., submitted 2014
Predict targets
http://goo.gl/vPOKS
http://goo.gl/iDJFR
8. Drug discovery is repetitive and there are 1000s of diseases
Drug discovery is high risk
Do we need robots or just smarter programs that discover the ideas we test?
9. 24 groups in this project use a single
Participants from India, Russia, South Africa, Europe, USA
10. TB Drug Accelerator
Another example of a big TB collaboration
7 Big Pharma and 4 academic institutes will open up targeted sections of their compound
libraries and share data with each other.
• Abbott
• AstraZeneca
• Bayer
• Eli Lilly
• GlaxoSmithKline
• Merck
• Sanofi
• Infectious Disease Research Institute (IDRI)
• NIH National Institute of Allergy and
Infectious Diseases
• Texas A&M University
• Weill Cornell Medical College
11. The Big Picture
• This did not happen overnight – 10 years to get here!
• Collaboration and selective secure sharing is key – move
ideas and data – to clinical compounds
• Domain expertise in drug discovery
• Bring scientists together globally
• Grants can accelerate / catalyze collaboration
• Grants can fund further technology development
• Impact how we develop therapies
Editor's Notes
CDD is 10 yrs old
SaaS is not new
Being on cloud, personal cloud is not new
Sharing data , collaborations is not new
We were first, we helped build foundation
What we do next is important and depends on you
Molecules and biology e.g. PubChem
Molecules and analytical data e.g. ChemSpider
These are massive..primarily look ups - not private ....not CDD
Standalone, little integration and lots of errors
Need to use caution
CDD has lots of public data
How to expose high value data
How to create addition high value datasets
TB molecules and targets
TB in vivo mouse data
We developed a mobile app yrs before any of our competitors
Easy use
Expose user to data
CDD brand recognition
Start something that can grow
App becomes way to fast prototype ideas
Data visualization, output